Anastrozole for men is an off-label use of a drug approved only for breast cancer in women. It blocks aromatase, the enzyme that converts testosterone into estradiol, which raises testosterone and lowers estrogen. That sounds ideal on paper, but the evidence is mixed and the risk to bone is real. For most men with low testosterone, it is not a first-choice treatment, and it works best in a few narrow situations under close monitoring.
What does anastrozole actually do in a man’s body?
Men make estradiol by converting a fraction of their testosterone through aromatase, an enzyme concentrated in fat tissue. Anastrozole is an aromatase inhibitor, so it clamps down on that conversion. The result is less estradiol and, because the pituitary sees less estrogen feedback, more signaling to the testes and higher testosterone. That mechanism is the whole appeal: it raises a man’s own testosterone rather than replacing it from outside.
The catch is that estradiol is not a female hormone that men happen to carry. Men need it. It regulates bone density, libido, and aspects of mood and metabolism. Push estradiol too low and problems follow, which is why this drug is easy to misuse when it is chased for a number on a lab report rather than a defined clinical goal.
Is it approved, and what does that mean for you?
The DailyMed prescribing information lists anastrozole for hormone-receptor-positive breast cancer in postmenopausal women. There is no labeled indication for men, no labeled male dose, and no labeled male safety profile. Prescribing it to a man is off-label, which is legal and often appropriate but shifts more of the responsibility onto the prescriber and the monitoring plan. It is worth understanding that distinction plainly rather than assuming approval that does not exist.
What do the trials say about benefit?
The most useful evidence comes from a randomized controlled trial in older men with low testosterone, published in 2015, that compared anastrozole against testosterone and placebo. Testosterone treatment raised levels and improved several measures. Anastrozole raised testosterone too, but it did not deliver the same benefit, and it lowered estradiol enough to reduce spine bone mineral density. A companion analysis in 2016 looked at cardiometabolic markers and again did not show anastrozole outperforming testosterone.
That is the honest headline: as a general substitute for testosterone therapy in men with hypogonadism, anastrozole underperforms and carries a bone cost. Where it holds more interest is in specific groups. A 2020 study found aromatase inhibitors combined with weight loss improved the hormonal profile of obese hypogonadal men, since excess fat tissue drives extra aromatase activity. And a 2021 review described the clinical application of aromatase inhibitors in treating male infertility, where preserving the body’s own testosterone production and sperm output matters in a way that external testosterone can undermine.
See also: Cybersecurity Best Practices for Businesses
How is anastrozole dosed in men?
There is no established labeled dose for men, so any figure comes from research settings or clinical practice rather than an approved regimen. The older-men trial used roughly 1 mg daily. In practice, many clinicians use lower and less frequent dosing, such as 1 mg once or twice a week, precisely because the daily dose can flatten estradiol too aggressively. Dosing is titrated to bloodwork and symptoms, not set once and forgotten. Guidance on how the drug fits alongside testosterone protocols, including why estradiol targets matter, is covered in practical detail elsewhere, such as as FormBlends explains among the physician-supervised telehealth options a man might consider alongside more established programs from providers like Hims and Hers, Ro, or Henry Meds.
No responsible resource, including this one, should hand out a self-dosing schedule for a man to run alone. The margin between helpful and harmful is narrow, and it is defined by lab values that only a prescriber tracking you over time can interpret.
How does it compare to the alternatives?
| Option | Best-supported use | Main drawback |
|---|---|---|
| Anastrozole | Selected fertility cases, some obese hypogonadal men | Off-label, lowers estradiol, reduces bone density |
| Testosterone therapy | Confirmed symptomatic hypogonadism | Suppresses fertility, needs monitoring |
| Weight loss and lifestyle | Obesity-related low testosterone | Slow, hard to sustain |
| Treating the underlying cause | Functional hypogonadism | Depends on an identifiable driver |
The Endocrine Society clinical practice guideline on testosterone therapy, and the Society for Endocrinology guidelines, both center on confirmed hypogonadism and do not position aromatase inhibitors as a routine treatment. A primary care primer on testosterone replacement reaches the same practical conclusion, and an Integrated Diabetes and Endocrine Academy consensus on men with type 2 diabetes and functional hypogonadism keeps the focus on established therapy and metabolic drivers rather than aromatase inhibition.
What are the real risks?
Bone is the clearest one. The randomized evidence showed reduced spine bone density with anastrozole, and men who run estradiol low for months to years risk long-term fragility. Beyond bone, driving estradiol too far down tends to worsen the very symptoms men hope to fix: low libido, poor mood, joint aches. There are also the effects listed for the drug generally, including hot flashes and possible liver enzyme changes. Because none of this is characterized in an approved male population, monitoring bloodwork, symptoms, and periodically bone health is not optional if the drug is used at all.
Key takeaways
- Anastrozole in men is entirely off-label; there is no FDA-approved male dose or indication.
- A randomized trial found it underperformed testosterone and reduced bone density.
- Its clearer roles are narrow: some fertility cases and obese hypogonadal men alongside weight loss.
- Estradiol is needed by men, so lowering it too far is the central risk.
- Any use should be titrated to labs and monitored by a prescriber, not self-managed.
Frequently asked questions
Is anastrozole approved for use in men?
No. Anastrozole is FDA-approved for breast cancer in women. Every use in men is off-label, meaning a clinician prescribes an approved drug for a condition outside its labeled indication based on judgment and evidence.
What dose of anastrozole do men usually take?
There is no established labeled dose for men. Studies in men have used roughly 1 mg daily or 1 mg once or twice weekly, but dosing is individualized by a prescriber and guided by bloodwork rather than a fixed number.
Does anastrozole raise testosterone in men?
It can. By blocking the conversion of testosterone to estradiol, it lifts testosterone in many men. Whether that translates into meaningful benefit, and at what cost to bone, is the real question the trials examine.
What is the biggest risk of anastrozole in men?
Lowering estradiol too far. Men need estradiol for bone health, and randomized trials found reduced bone density with aromatase inhibition, which makes long-term unmonitored use a poor trade for most men.
Is anastrozole better than testosterone therapy?
For most men with hypogonadism, no. A head-to-head randomized trial found testosterone gel improved outcomes while anastrozole did not match it and reduced bone density. Anastrozole has narrower, specific roles such as some fertility cases.
